June 14, 2005 In another session marked by low volatility, stocks closed generally higher, though Nasdaq did not get out of negative territory until the closing bell. The Centient Biotech 200 added on 5 points to end at 3335.27, a rise of .16%. The S&P 500 was up .26% and Nasdaq was, for all practical purposes, flat. Mylan announced a stock buy-back plan and a huge upward revision to earnings guidance, Edwards will revise its revolutionary heart valve replacement surgery, Amylin impressed observers with its recently approved insulin-like drug, Dynavax presented strong data for its hepatitis B vaccine, Trimeris signed a deal with ChemBridge to develop HIV medications, Biogen Idec says that Rituxan, together with galiximab, extended event-free survival for non-Hodgkins lymphoma, Santarus said Zegrid did a better job of suppressing gastric acid than blockbuster Protonix, and rumors circulated around SciClone, once again. More details...
